1134. Assessment of Enhancement Pattern at Pre-Treatment CT for Survival Prognosis in Recommended TACE Candidates with Hepatocellular Carcinoma
Authors* Denotes Presenting Author
Fang-Ming Chen;
The Affiliated Wuxi No.2 People’s Hospital of Nanjing Medical University
Zhui-Yang Zhang *;
The Affiliated Wuxi No.2 People’s Hospital of Nanjing Medical University
Objective:
Transarterial chemoembolization (TACE) is the recommended treatment option for patients with intermediate stage hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the relevance of different enhancement patterns at pretreatment CT for prognosis of overall survival (OS).
Materials and Methods:
Data of 92 patients with intermediate-stage HCC undergoing TACE as initial treatment and preoperative CT scan were retrospectively collected. Four enhancement patterns of the largest target lesion (homogeneous hypoenhancement [type 1], homogeneous hyperenhancement [type 2], heterogeneous enhancement with septum-like structure [type 3] and heterogeneous enhancement with irregular ring-like structures [type 4]) were assessed. Kaplan Meier analysis was performed to descriptively assess OS. A Cox proportional hazards model was used to determine the predictive factors for OS.
Results:
Kaplan-Meier analysis yielded a median OS of 19 (95%confidence interval [CI], 17.1–24.0) months. Survival analysis showed significant differences depending on enhancement patterns (hazard ratio, 0.36; p = 0.017). Patients with homogeneous enhancement patterns (Type 1 and 2) had a median OS of 31.3 (95%CI, 24.5–4.1) months. Patients with heterogeneous enhancement patterns (Type 3 and 4) showed a median OS of 12.5 (95%CI, 9.6–16.1) months.
Conclusion:
The enhancement pattern of the largest HCC lesion at pretreatment CT may be a useful predictor for survival prognosis in recommended TACE candidates with HCC, and has the potential to be used as an additional parameter for treatment stratification.
